Boule Diagnostics secured major tender in India
A major tender has been secured in India, including a large number of instruments as well as reagents and controls. This complex tender process has been ongoing for an extended period of time and has been brought to a successful conclusion for Boule by our local country manager in close collaboration with one of our key distributors. Deliveries of 650 instruments are expected to take place during the third and fourth quarter of 2018.
Winning this tender further strengthens Boule´s position in the Indian market and can lead to further instrument sales in addition to the ongoing reagent and control sales supporting the installed base.
For further information, please contact:
Fredrik Dalborg, CEO and President, Boule Diagnostics AB, phone +46 70-558 51 05
Christina Rubenhag, CFO Boule Diagnostics AB, phone +46 70-546 72 22
About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA and Mexico. The company’s products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. www.boule.com
This information is information that Boule Diagnostics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15.15 CET on August 7, 2018.
Latest news
-
Kallelse till extra bolagsstämma i Boule Diagnostics AB (publ) 4 Nov, 2026
-
Boule Diagnostics AB resolves on a fully secured rights issue of approximately MSEK 93 with an over-allotment option of up to approximately MSEK 63 subject to approval by the Extraordinary General Meeting 4 Nov, 2026
-
Boule Diagnostics AB beslutar om en fullt säkerställd företrädesemission om cirka 93 MSEK med en övertilldelningsoption om upp till cirka 63 MSEK villkorat av godkännande från extra bolagsstämma 4 Nov, 2026
-
Boule Diagnostics renodlar verksamheten mot förbrukningsvaror, service och OEM – avvecklar instrumentverksamheten 4 Nov, 2026
-
Boule Diagnostics refocuses its operations on consumables, service and OEM – discontinues its instrument business 4 Nov, 2026
-
Boule Diagnostics delårsrapport Q3 2026 23 Oct, 2026
-
Boule Diagnostics Interim Report Q3 2026 23 Oct, 2026
-
Boule Diagnostics Strengthens Long-Term Strategic Collaboration in India 6 Oct, 2026